CN102573890A - 经过修饰的因子ix多肽及其用途 - Google Patents

经过修饰的因子ix多肽及其用途 Download PDF

Info

Publication number
CN102573890A
CN102573890A CN2010800431356A CN201080043135A CN102573890A CN 102573890 A CN102573890 A CN 102573890A CN 2010800431356 A CN2010800431356 A CN 2010800431356A CN 201080043135 A CN201080043135 A CN 201080043135A CN 102573890 A CN102573890 A CN 102573890A
Authority
CN
China
Prior art keywords
fix
polypeptide
amino acid
gather
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800431356A
Other languages
English (en)
Chinese (zh)
Inventor
A.布鲁克斯
C.帕特尔
蒋晓乔
U.格里赞
H.阿佩勒
王俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102573890(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CN102573890A publication Critical patent/CN102573890A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2010800431356A 2009-07-31 2010-08-02 经过修饰的因子ix多肽及其用途 Pending CN102573890A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
US61/230,551 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN102573890A true CN102573890A (zh) 2012-07-11

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800431356A Pending CN102573890A (zh) 2009-07-31 2010-08-02 经过修饰的因子ix多肽及其用途

Country Status (21)

Country Link
US (1) US20120164130A1 (enExample)
EP (1) EP2461821A4 (enExample)
JP (1) JP2013500726A (enExample)
KR (1) KR20120060209A (enExample)
CN (1) CN102573890A (enExample)
AU (1) AU2010278721A1 (enExample)
BR (1) BR112012002072A2 (enExample)
CA (1) CA2769258A1 (enExample)
CL (1) CL2012000238A1 (enExample)
CR (1) CR20120052A (enExample)
CU (3) CU20120018A7 (enExample)
DO (1) DOP2012000030A (enExample)
EA (1) EA201290069A1 (enExample)
EC (1) ECSP12011637A (enExample)
GT (1) GT201200023A (enExample)
IN (1) IN2012DN00908A (enExample)
MX (1) MX2012001346A (enExample)
PE (1) PE20121643A1 (enExample)
SG (1) SG178119A1 (enExample)
WO (1) WO2011014890A1 (enExample)
ZA (1) ZA201200716B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105451774A (zh) * 2013-04-28 2016-03-30 拜耳医药保健有限公司 用于诱导对凝固因子蛋白的免疫耐受的组合物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
ES2985035T3 (es) 2008-09-15 2024-11-04 Uniqure Biopharma B V Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR102325780B1 (ko) * 2010-07-30 2021-11-12 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
ES2656613T3 (es) * 2011-12-19 2018-02-27 Dilafor Ab Glicosaminoglicanos no anticoagulantes que comprenden unidades de repetición de disacáridos y su uso médico
JP2015536148A (ja) * 2012-11-20 2015-12-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変第ｉｘ因子タンパク質についての方法および組成物
CA2901928C (en) * 2013-03-13 2017-10-10 Eli Lilly And Company Modified canine leptin polypeptides
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
JP7181855B2 (ja) * 2016-07-27 2022-12-01 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｉｘ因子の機能を調節するための組成物及び方法
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CN113260701A (zh) 2018-10-18 2021-08-13 英特利亚治疗股份有限公司 用于表达因子ix的组合物和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
US20080102115A1 (en) * 2006-06-19 2008-05-01 Jorge Oyhenart Modified coagulation factor IX polypeptides and use thereof for treatment
US20080167219A1 (en) * 2007-01-09 2008-07-10 Shu-Wha Lin Recombinant human factor ix and use thereof
US20090081188A1 (en) * 2003-12-03 2009-03-26 Neose Technologies, Inc. Glycopegylated factor ix

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
US20090081188A1 (en) * 2003-12-03 2009-03-26 Neose Technologies, Inc. Glycopegylated factor ix
US20080102115A1 (en) * 2006-06-19 2008-05-01 Jorge Oyhenart Modified coagulation factor IX polypeptides and use thereof for treatment
US20080167219A1 (en) * 2007-01-09 2008-07-10 Shu-Wha Lin Recombinant human factor ix and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHUETTRUMPF J等: "Factor IX variants improve gene therapy efficacy for hemophilia B", 《BLOOD》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105451774A (zh) * 2013-04-28 2016-03-30 拜耳医药保健有限公司 用于诱导对凝固因子蛋白的免疫耐受的组合物

Also Published As

Publication number Publication date
GT201200023A (es) 2014-01-27
CA2769258A1 (en) 2011-02-03
KR20120060209A (ko) 2012-06-11
ECSP12011637A (es) 2012-02-29
EP2461821A4 (en) 2013-07-03
CL2012000238A1 (es) 2012-10-05
EA201290069A1 (ru) 2012-07-30
PE20121643A1 (es) 2012-11-25
ZA201200716B (en) 2013-07-31
CU20130058A7 (es) 2013-06-28
US20120164130A1 (en) 2012-06-28
EP2461821A1 (en) 2012-06-13
AU2010278721A1 (en) 2012-02-16
CR20120052A (es) 2012-06-04
BR112012002072A2 (pt) 2016-11-08
CU20120018A7 (es) 2012-06-21
DOP2012000030A (es) 2012-02-29
WO2011014890A1 (en) 2011-02-03
CU20130057A7 (es) 2013-06-28
MX2012001346A (es) 2012-02-17
IN2012DN00908A (enExample) 2015-04-03
JP2013500726A (ja) 2013-01-10
SG178119A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
US20120164130A1 (en) Modified Factor IX Polypeptides and Uses Thereof
CA2721362A1 (en) Site-directed modification of factor ix
KR102068133B1 (ko) 혈액 응고 단백질 복합체
JP5876208B2 (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
US20090252720A1 (en) Prolonged FIX Analogues and Derivatives
ES2731626T3 (es) Catalizadores nucleofílicos para enlace oxima
CN102083856A (zh) 经修饰的因子ix多肽及其用途
CA2571292A1 (en) Polymer-factor ix moiety conjugates
KR102326360B1 (ko) 옥심 결합을 위한 친핵성 촉매
TW201247709A (en) Therapeutic proteins with increased half-life and methods of preparing same
JP2018035192A (ja) 血液凝固タンパク質複合体
HK1172840A (en) Modified factor ix polypeptides and uses thereof
HK1153383A (zh) 因子ix的定點修飾

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172840

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1172840

Country of ref document: HK